Prezista oral suspension launched

Prezista (darunavir) is now available as a 100mg/ml oral suspension.

Prezista (darunavir) is licensed for use in all adult patients as well as in antiretroviral treatment-experienced paediatric patients aged 3 years and over who weigh at least 15kg
Prezista (darunavir) is licensed for use in all adult patients as well as in antiretroviral treatment-experienced paediatric patients aged 3 years and over who weigh at least 15kg

Prezista (darunavir) is indicated in combination with low dose ritonavir and together with other antiretrovirals for the treatment of HIV-1 infection.

It may be used to administer doses to paediatric patients or in adult patients unable to swallow tablets.

View Prezista drug record

Further information: Janssen-Cilag Ltd

Follow MIMS on Twitter


Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.